[Maximal androgen blockade and maximal androgen blockade combined with 125I brachytherapy for prostatic cancer].
OBJECTIVE
To assess the effect of the maximal androgen blockade(MAB) and MAB combined with 125I brachytherapy on prostatic cancer.


METHODS
Forty-four patients with prostatic cancer (from 1993 to 2002), 28 at pathologic stage C and 16 at stage D, were analyzed retrospectively. Thirty-five of them were treated by bilateral orchidectomy and anti-androgen drugs, i.e. MAB, and 9 treated by MAB combined with 125I brachytherapy. The survival rates and the variation of serum prostate-specific antigen (PSA) levels between pre- and post-treatment were compared.


RESULTS
The level of PSA decreased from 60.3 micrograms/L to 12.1 micrograms/L in 35 patients treated by MAB, and from 72.1 micrograms/L to 3.6 micrograms/L in 9 patients treated by MAB combined with 125I brachytherapy after 6 months. The post-treatment survival rates were 81.3% (26/32, excluding 3 deaths by other diseases) for patients treated by MAB after a mean follow-up of 39.2 (9-84) months and 100% for patients by MAB combined with 125I brachytherapy after a mean follow-up of 13(7-24) months.


CONCLUSIONS
MAB and MAB combined with 125I brachytherapy are effective for patients with prostatic cancer.
Department of Urology, Affiliated Hospital of Medical College of Southeast University, Nanjing, Jiangsu 210009, China.
Yun
Y
Su
Mao-Yin
MY
Yao
Zhang
Z
Yuan
Jian-Jun
JJ
Yang
Jing
J
Liu
Xiang-Nong
XN
Hu
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D001918:Brachytherapy; D003131:Combined Modality Therapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D012189:Retrospective Studies; D015996:Survival Rate
D000726:Androgen Antagonists; D007457:Iodine Radioisotopes